Oleoyl-estrone does not have direct estrogenic effects on rats.
The estrogenic effects of oleoyl-estrone (OE) administration, either though continuous i.v. infusion with osmotic minipumps or administered by daily oral gavage, were studied. Binding of OE to human recombinant purified alpha receptors was negligible, and that of estrone (E1) was only a fraction of 17beta-estradiol (E2) binding. Intravenous--but not oral--OE administration resulted in marked increases of both E1 and E2 in rat plasma, but oral OE did not induce significant changes in either plasma hormone in Wistar or Zucker rats. The weight of uteri and ovaries increased with time of administration in Zucker rats treated with i.v. OE, but inguinal mammary gland proliferation between subcutaneous adipose tissue was even more marked. Oral administration of OE, however, did not increase either uterine weight or mammary gland proliferation, even at doses (10 micromol/kg x d) higher than those given i.v. (3.5 micromol/kg x d). The results indicate that i.v. administration of OE resulted in limited estrogenic effects mainly due to the high accumulation of E1 giving rise to significant increases in E2. On the other hand, oral administration of OE, even at higher daily doses, did not increase the circulating levels of either estrogen and, therefore, there were no significant effects on mammary gland proliferation or uterine weight. The oral administration of OE as a slimming drug, then, do not result in estrogenic side effects over a wide range of daily doses.
Cabot
C
C
Centre Especial de Recerca en Nutrició i Ciència dels Aliments, Facultat de Biologia, Universitat de Barcelona, Spain.
Grasa
M M
MM
Massanés
R M
RM
de Matteis
R
R
Cinti
S
S
Fernández-López
J A
JA
Remesar
X
X
Alemany
M
M
D000273:Adipose Tissue / Q000187:drug effects / Q000473:pathology; D000284:Administration, Oral; D000818:Animals; D019440:Anti-Obesity Agents / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology*; D001940:Breast / Q000187:drug effects / Q000254:growth & development / Q000473:pathology; D004305:Dose-Response Relationship, Drug; D004958:Estradiol / Q000097:blood; D045166:Estradiol Congeners / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology*; D047628:Estrogen Receptor alpha; D004970:Estrone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000097:blood / Q000378:metabolism / Q000494:pharmacology*; D005260:Female; D006801:Humans; D015918:Infusion Pumps, Implantable; D007262:Infusions, Intravenous; D009829:Oleic Acids / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology*; D009929:Organ Size / Q000187:drug effects; D010053:Ovary / Q000187:drug effects / Q000473:pathology; D051381:Rats; D017208:Rats, Wistar; D011924:Rats, Zucker; D011960:Receptors, Estrogen / Q000378:metabolism; D020845:Selective Estrogen Receptor Modulators / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology*; D014599:Uterus / Q000187:drug effects / Q000473:pathology
D019440:Anti-Obesity Agents; D045166:Estradiol Congeners; D047628:Estrogen Receptor alpha; D009829:Oleic Acids; D011960:Receptors, Estrogen; D020845:Selective Estrogen Receptor Modulators; D004970:Estrone; D004958:Estradiol; C108709:oleoyl-estrone